Newron Pharmaceuticals S.p.A. (0QOI.L)

Newron Pharmaceuticals S.p.A. (0QOI.L) — VMCI valuation read

Across 120 indicators, Newron Pharmaceuticals S.p.A. (0QOI.L) lands at VMCI 42/100. The Healthcare sector median is 50, so the 8-point below-median read is the active comparison. Pillar weighting on the score: Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%.

No material Form 4 disclosures landed on 0QOI.L in the past 30 days. Quiet insider tape removes one signal source; the active reads stay with the trailing-twelve-month financials and the next 10-Q.

**Investor frame.** On Value, 0QOI.L trades at 21.0x earnings, 17% above the Healthcare median of 18.0x; the EV/EBITDA delta of -2.0x reinforces that single line. On Quality, ROIC of 17.0% sits 7.0pp above the Healthcare median (10.0%). On Risk, net debt to EBITDA of 0.5x leaves covenant headroom for 0QOI.L on the trailing balance sheet.

0QOI.L rose 3.8% over the trailing 7 days, with a -23.3% read on a 30-day basis.